Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.

Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs LYMPHIR is expected to launch within the next five months LYMPHIR's approval ...

Please provide your email address to receive an email when new articles are posted on . Cutaneous adverse events with GLP-1 receptor agonists are rare but can include rash and pruritus. Clinicians ...

A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata University Graduate ...

C5aR1 expression correlates with increased metastasis risk and poor survival in cSCC patients. The tumor microenvironment, especially fibroblasts, influences C5aR1 expression and cSCC progression.

The human epidermal growth factor receptor (HER1/EGFR) is dysregulated in many solid tumors, making it an attractive target for anticancer therapy. A number of agents that target this receptor are in ...

Niigata, Japan - A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata ...

Lung and bronchus cancer in young females: Exploring sex disparities across diverse racial and ethnic groups in the U.S. (2000-2020). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting ...